nach oben

Breast Cancer

Erschienen in:

31.01.2018 | Original Article

Correlation of FANCM expression with clinical factors in luminal B breast cancer

verfasst von: Yiran Wang, Junnan Wang, Fei Long, Ning Wang, Bingbing Zhang, Huan Han, Yajie Wang

Erschienen in: Breast Cancer | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The genotype of Fanconi Anemia complementation group M (FANCM) was previously found to be associated with breast cancer risk in several populations. Here, we studied the expression of FANCM and its correlation with clinical characteristics in Chinese patients with breast cancer.

Methods

We performed an immunohistochemical study of FANCM protein in clinical breast cancer tissues from 310 patients along with 44 adjacent tissues.

Results

FANCM protein level is lower in triple-negative breast cancer tissues than in other subtypes (P = 0.008). In addition, high FANCM expression correlated with pathology type IDC (P = 0.040), estrogen receptor positive (P < 0.001), progesterone receptor positive (P = 0.001), and low Ki-67 status (P = 0.003). Multivariate analysis revealed that FANCM status was an independent prognostic factor for overall survival (P = 0.017) in luminal B breast cancer.

Conclusions

FANCM levels are significantly associated with different subtypes of human breast cancer. Specifically, FANCM could play a role in the progression of luminal B breast cancer.

Siegel R, Miller K, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRefPubMed

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China. CA Cancer J Clin. 2015;66(2):115–32.CrossRef

Heilmann K. Epigenetic characterization of the C3(1) SV40T mouse model of human breast cancer. 2017.

Holm J, Eriksson L, Ploner A, Eriksson M, Rantalainen M, Li J, et al. Assessment of breast cancer risk factors reveals subtype heterogeneity. Cancer Res. 2017;77(13):3708–17.CrossRefPubMed

Martín-Sánchez E, Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Córdoba A, Vicente-García F, et al. CDH22hypermethylation is an independent prognostic biomarker in breast cancer. Clin Epigenetics. 2017;9(1):7.CrossRefPubMedPubMedCentral

Ling C, Huang J, Yan Z, Li Y, Ohzeki M, Ishiai M, et al. Bloom syndrome complex promotes FANCM recruitment to stalled replication forks and facilitates both repair and traverse of DNA interstrand crosslinks. Cell Discov. 2016;2:16047.CrossRefPubMedPubMedCentral

Ali AM, Singh TR, Meetei AR. FANCM-FAAP24 and FANCJ: FA proteins that metabolize DNA. Mutat Res. 2009;668(1–2):20–6.CrossRefPubMedPubMedCentral

Xue X, Sung P, Zhao X. Functions and regulation of the multitasking FANCM family of DNA motor proteins. Genes Dev. 2015;29(17):1777–88.CrossRefPubMedPubMedCentral

Rohleder F, Huang J, Xue Y, Kuper J, Round A, Seidman M, et al. FANCM interacts with PCNA to promote replication traverse of DNA interstrand crosslinks. Nucl Acids Res. 2016;44(7):3219–32.CrossRefPubMedPubMedCentral

10.

Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, et al. Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget. 2017;8(31):50930–40.CrossRefPubMedPubMedCentral

11.

Neidhardt G, Hauke J, Ramser J, Gross E, Gehrig A, Muller CR, et al. Association between loss-of-function mutations within the FANCM gene and early-onset familial breast cancer. JAMA Oncol. 2017;3(9):1245–8.CrossRefPubMed

12.

Catucci I, Osorio A, Arver B, Neidhardt G, Bogliolo M, Zanardi F, et al. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. Genet Med. 2017. https://doi.org/10.1038/gim.2017.123.PubMedCrossRef

13.

Kiiski JI, Fagerholm R, Tervasmaki A, Pelttari LM, Khan S, Jamshidi M, et al. FANCM c.5101C > T mutation associates with breast cancer survival and treatment outcome. Int J Cancer. 2016;139(12):2760–70.CrossRefPubMedPubMedCentral

14.

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.CrossRefPubMedPubMedCentral

15.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.CrossRefPubMed

16.

Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, et al. FANCM c.5791C > T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Hum Mol Genet. 2015;24(18):5345–55.CrossRefPubMedPubMedCentral

17.

Rashid MU, Muhammad N, Khan FA, Hamann U. Absence of the FANCM c.5101C > T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan. Breast Cancer Res Treat. 2015;152(1):229–30.CrossRefPubMed

18.

Kiiski JI, Pelttari LM, Khan S, Freysteinsdottir ES, Reynisdottir I, Hart SN, et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci USA. 2014;111(42):15172–7.CrossRefPubMedPubMedCentral

19.

Kiiski JI, Tervasmaki A, Pelttari LM, Khan S, Mantere T, Pylkas K, et al. FANCM mutation c.5791C > T is a risk factor for triple-negative breast cancer in the Finnish population. Breast Cancer Res Treat. 2017;66(1):217–26.CrossRef

20.

Pan X, Drosopoulos WC, Sethi L, Madireddy A, Schildkraut CL, Zhang D. FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres. Proc Natl Acad Sci USA. 2017;114(29):E5940–9.CrossRefPubMedPubMedCentral

21.

Krammer J, Pinker-Domenig K, Robson ME, Gonen M, Bernard-Davila B, Morris EA, et al. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2017;163(3):565–71.CrossRefPubMedPubMedCentral

22.

Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):71–80.CrossRefPubMed

23.

Sinn HP, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, et al. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer. 2017;17(1):124.CrossRefPubMedPubMedCentral

24.

Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Bellon JR, et al. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat. 2017;161(1):173–9.CrossRefPubMed

25.

Cheang MCU, Chia SK, Voduc D, Gao DX, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.CrossRefPubMedPubMedCentral

26.

Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363–71.CrossRefPubMedPubMedCentral

27.

Berton S, Cusan M, Segatto I, Citron F, D’Andrea S, Benevol S, et al. Loss of p27 kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. Sci Rep. 2017;7(1):595.CrossRefPubMedPubMedCentral

28.

Schwab RA, Blackford AN, Niedzwiedz W. ATR activation and replication fork restart are defective in FANCM-deficient cells. EMBO J. 2010;29(4):806–18.CrossRefPubMedPubMedCentral

Titel: Correlation of FANCM expression with clinical factors in luminal B breast cancer
verfasst von: Yiran Wang
Junnan Wang
Fei Long
Ning Wang
Bingbing Zhang
Huan Han
Yajie Wang
Publikationsdatum: 31.01.2018
Verlag: Springer Japan
Erschienen in: Breast Cancer / Ausgabe 4/2018
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-018-0841-0

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Correlation of FANCM expression with clinical factors in luminal B breast cancer

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Clinical development of CDK4/6 inhibitor for breast cancer

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)

Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer

Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials

Do you know how to get the J-START quality assurance guideline?

Effect of the normal mammary differentiation regulator ELF5 upon clinical outcomes of triple negative breast cancers patients

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie